MAFLD: what 2 years of the redefinition of fatty liver disease has taught us
Metabolic dysfunction–associated fatty liver disease (MAFLD) has appeared as the leading liver disease worldwide. Whereas the terminology nonalcoholic fatty liver disease (NAFLD) mainly reflected a negative selection and exclusion of alcohol-related liver disease (ALD), the new definition made its f...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-11-01
|
| Series: | Therapeutic Advances in Endocrinology and Metabolism |
| Online Access: | https://doi.org/10.1177/20420188221139101 |
| _version_ | 1811216451238887424 |
|---|---|
| author | Felix Grabherr Christoph Grander Maria Effenberger Julian Schwärzler Herbert Tilg |
| author_facet | Felix Grabherr Christoph Grander Maria Effenberger Julian Schwärzler Herbert Tilg |
| author_sort | Felix Grabherr |
| collection | DOAJ |
| description | Metabolic dysfunction–associated fatty liver disease (MAFLD) has appeared as the leading liver disease worldwide. Whereas the terminology nonalcoholic fatty liver disease (NAFLD) mainly reflected a negative selection and exclusion of alcohol-related liver disease (ALD), the new definition made its focus on the association of MAFLD with overweight/obesity, type 2 diabetes and metabolic risk factors especially also in normal weight/lean subjects. Several studies from the past 2 years have now used the new definition and have provided substantial information that this new definition might be accurate. Studies from the past 2 years have provided evidence that the new definition might be especially advantageous in the characterization and identification of patients with significant fibrosis. This has also been demonstrated in the well-known Rotterdam study in which the MAFLD-only group showed a higher rate of fibrosis and liver stiffness. MAFLD might also be able to predict all-cause mortality as demonstrated in the Third National Health and Nutrition Examination Survey. Furthermore, MAFLD might improve characterization of the cardiovascular risk of this patient population. As the term MAFLD has not yet been accepted universally, it remains important to coordinate efforts globally to adapt to this new definition and especially involve all specialities dealing with metabolic disorders such as diabetologists to further improve its definition and to prepare the medical community for its future use. The aim of this review is to summarize and critically address evidence emerging over the past 2 years that usage of the term MAFLD could be helpful in daily clinical practice. |
| first_indexed | 2024-04-12T06:39:16Z |
| format | Article |
| id | doaj.art-a0e13b3310624454922123155366466a |
| institution | Directory Open Access Journal |
| issn | 2042-0196 |
| language | English |
| last_indexed | 2024-04-12T06:39:16Z |
| publishDate | 2022-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Endocrinology and Metabolism |
| spelling | doaj.art-a0e13b3310624454922123155366466a2022-12-22T03:43:45ZengSAGE PublishingTherapeutic Advances in Endocrinology and Metabolism2042-01962022-11-011310.1177/20420188221139101MAFLD: what 2 years of the redefinition of fatty liver disease has taught usFelix GrabherrChristoph GranderMaria EffenbergerJulian SchwärzlerHerbert TilgMetabolic dysfunction–associated fatty liver disease (MAFLD) has appeared as the leading liver disease worldwide. Whereas the terminology nonalcoholic fatty liver disease (NAFLD) mainly reflected a negative selection and exclusion of alcohol-related liver disease (ALD), the new definition made its focus on the association of MAFLD with overweight/obesity, type 2 diabetes and metabolic risk factors especially also in normal weight/lean subjects. Several studies from the past 2 years have now used the new definition and have provided substantial information that this new definition might be accurate. Studies from the past 2 years have provided evidence that the new definition might be especially advantageous in the characterization and identification of patients with significant fibrosis. This has also been demonstrated in the well-known Rotterdam study in which the MAFLD-only group showed a higher rate of fibrosis and liver stiffness. MAFLD might also be able to predict all-cause mortality as demonstrated in the Third National Health and Nutrition Examination Survey. Furthermore, MAFLD might improve characterization of the cardiovascular risk of this patient population. As the term MAFLD has not yet been accepted universally, it remains important to coordinate efforts globally to adapt to this new definition and especially involve all specialities dealing with metabolic disorders such as diabetologists to further improve its definition and to prepare the medical community for its future use. The aim of this review is to summarize and critically address evidence emerging over the past 2 years that usage of the term MAFLD could be helpful in daily clinical practice.https://doi.org/10.1177/20420188221139101 |
| spellingShingle | Felix Grabherr Christoph Grander Maria Effenberger Julian Schwärzler Herbert Tilg MAFLD: what 2 years of the redefinition of fatty liver disease has taught us Therapeutic Advances in Endocrinology and Metabolism |
| title | MAFLD: what 2 years of the redefinition of fatty liver disease has taught us |
| title_full | MAFLD: what 2 years of the redefinition of fatty liver disease has taught us |
| title_fullStr | MAFLD: what 2 years of the redefinition of fatty liver disease has taught us |
| title_full_unstemmed | MAFLD: what 2 years of the redefinition of fatty liver disease has taught us |
| title_short | MAFLD: what 2 years of the redefinition of fatty liver disease has taught us |
| title_sort | mafld what 2 years of the redefinition of fatty liver disease has taught us |
| url | https://doi.org/10.1177/20420188221139101 |
| work_keys_str_mv | AT felixgrabherr mafldwhat2yearsoftheredefinitionoffattyliverdiseasehastaughtus AT christophgrander mafldwhat2yearsoftheredefinitionoffattyliverdiseasehastaughtus AT mariaeffenberger mafldwhat2yearsoftheredefinitionoffattyliverdiseasehastaughtus AT julianschwarzler mafldwhat2yearsoftheredefinitionoffattyliverdiseasehastaughtus AT herberttilg mafldwhat2yearsoftheredefinitionoffattyliverdiseasehastaughtus |